Company news
Compugen Ltd. news in 2024
Compugen Ltd.'s news releases, calls and decks from 2024, newest first.
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
November 26, 2024
Compugen Reports Third Quarter 2024 Results
November 11, 2024
Compugen to Participate in Stifel 2024 Healthcare Conference
November 10, 2024
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
November 4, 2024
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 28, 2024
Compugen to Present New Clinical Data at SITC 2024
October 6, 2024
Compugen to Present at Single Cell Genomics 2024 Conference
September 8, 2024
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
Compugen Reports Second Quarter 2024 Results
August 5, 2024
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
July 28, 2024
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
July 22, 2024
Compugen to Present at Upcoming Antibody Industrial Symposium
June 16, 2024
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
May 29, 2024
Compugen Reports First Quarter 2024 Results
May 19, 2024
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
May 15, 2024
Compugen Appoints David Silberman as Chief Financial Officer
May 14, 2024
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
May 5, 2024
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
April 24, 2024
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
April 9, 2024
Compugen to Participate in Two Upcoming Investor Conferences
April 2, 2024
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
March 10, 2024
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
March 5, 2024
Compugen Reports Fourth Quarter and Full Year 2023 Results
March 4, 2024
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
February 25, 2024
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
February 19, 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
February 14, 2024
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
January 7, 2024
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 7, 2024